What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @RichardPAConway: Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bi

      Richard Conway RichardPAConway

      3 years 1 month ago
      Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh
      RT @RichardPAConway: Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears

      Richard Conway RichardPAConway

      3 years 1 month ago
      Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development @RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m
      RT @RichardPAConway: Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal prog

      Richard Conway RichardPAConway

      3 years 1 month ago
      Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4
      RT @RichardPAConway: Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work.

      Richard Conway RichardPAConway

      3 years 1 month ago
      Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk
      RT @Yuz6Yusof: Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 1 month ago
      Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the mind and body sane. Dare to accept challenge? #ACRVirtual5K Run #ACR22 #rheumatologyrunners #wellbeing #foggy @RheumNow #RheumPix https://t.co/N9ulz8KPVw
      RT @RichardPAConway: Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events

      Richard Conway RichardPAConway

      3 years 1 month ago
      Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru
      RT @RichardPAConway: Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35

      Richard Conway RichardPAConway

      3 years 1 month ago
      Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35% vs 65% developed RA. MRI response 57% vs 29%. @RheumNow #ACR22 Abstr#0530 https://t.co/35M2sPkIbW https://t.co/S8K39jkCh0
      RT @ericdeinmd: Ab0675 #ACR22 DAH in APLS
      61 pts w APS, incident DAH
      85% h/o VTE, 51% thrombocyt 43% valvulopathy
      74% w

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab0675 #ACR22 DAH in APLS 61 pts w APS, incident DAH 85% h/o VTE, 51% thrombocyt 43% valvulopathy 74% were on a/c at time of DAH Relapse rate: 41% at 1 yr, 26% w/in 6 mos!!! Risks: triple pos, thrombocyt, IVIG, PLEX, ventilation Mortality 19% 1 yr, 38% 5 yrs @RheumNow #ACRBest https://t.co/g1uz2Giilc
      RT @ericdeinmd: Ab0676 #ACR22 Adrenal hemorrhage in APLS
      59 pts from SLE cohort + 181 from lit review
      65% prior VTE, 12%

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab0676 #ACR22 Adrenal hemorrhage in APLS 59 pts from SLE cohort + 181 from lit review 65% prior VTE, 12% CVA, 24% OB morbidity 46% thrombocyt, 21% had SLE 58% on a/c 69% b/l hemorrhage 63% adrenal insuff Radiol remission: 6% at 1 yr, 41% at 5yr Death 2% 1 yr, 11% at 5 @RheumNow https://t.co/EacifcN7Sd
      RT @ericdeinmd: Ab0683 #ACR22
      aPL Pts ANA pos vs neg:
      521 pts with +aPL Ab WO other autoimmune disease
      224 +ANA, 297 -A

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab0683 #ACR22 aPL Pts ANA pos vs neg: 521 pts with +aPL Ab WO other autoimmune disease 224 +ANA, 297 -ANA ANA+ ass w/ hemolytic anemia, thrombocyt, leukopenia, livedo, unexplained fetal death Trend for arthritis, aPL nephropathy @RheumNow https://t.co/3NHGymyL1C
      RT @ericdeinmd: Ab0685 #ACR22 APLS and prior COVID infection

      TKR patients at HSS:
      1/5 of patients had positive aPL Ab,

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab0685 #ACR22 APLS and prior COVID infection TKR patients at HSS: 1/5 of patients had positive aPL Ab, mostly low level aCL IgM Not associated with COVID infection or SARS-CoV-2 Ab @RheumNow https://t.co/HJpnUOrrxc
      RT @RichardPAConway: Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years

      Richard Conway RichardPAConway

      3 years 1 month ago
      Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years 61% vs 64%. Time to remission 19 months vs 16 months. @RheumNow #ACR22 Abstr#0532 https://t.co/ZRuqqaPHHU https://t.co/pDBHHtLEhs
      RT @DrCassySims: 🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest

      Identifying fetal myocardial targets in cong

      Catherine Sims, MD DrCassySims

      3 years 1 month ago
      🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest Identifying fetal myocardial targets in congenital heart block (CHB) Abstract #L13 🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w
      RT @RichardPAConway: Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial in

      Richard Conway RichardPAConway

      3 years 1 month ago
      Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial infection compared to HC. Causality or Reverse Causality? I think more likely reverse - disease related immunosuppresion @RheumNow #ACR22 Abstr#0535 https://t.co/i5iN3Db7rf https://t.co/2ynYF7Vqbl
      RT @ericdeinmd: Ab0674 #ACR22 HIT AND APLS??
      Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE w

      Eric Dein ericdeinmd

      3 years 1 month ago
      Ab0674 #ACR22 HIT AND APLS?? Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab: Not one ultimately met clinical criteria for HIT 1 pt had PF4 antibodies, SRA testing negative in ALL cases Thrombocytopenia w/ aPL Abs? Think APS 1st! @Rheumnow https://t.co/ZYZP5VZF0R

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×